Literature DB >> 12654656

Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis.

Matthew R Moore1, Françoise Perdreau-Remington, Henry F Chambers.   

Abstract

Heterogeneous resistance to vancomycin is thought to precede emergence of intermediate susceptibility to vancomycin in Staphylococcus aureus, but the clinical significance of heterogeneous resistance is unknown. Paired S. aureus isolates from a patient with endocarditis who relapsed after vancomycin treatment were tested for heterogeneous resistance to vancomycin. The pretreatment and the relapse clinical isolates (strains SF1 and SF2, respectively) were genotyped by pulsed-field gel electrophoresis. Susceptibility to vancomycin was assessed by the broth dilution method, population analysis, and time-kill studies and in the rabbit model of endocarditis. Strains SF1 and SF2 had similar genotypes, and the vancomycin MICs for the strains were </=2 micro g/ml. SF2 exhibited heterogeneous resistance to vancomycin. Vancomycin eradicated SF1 in the rabbit model of endocarditis, while SF2 persisted at pretreatment levels. Vancomycin treatment failure in this patient with endocarditis was attributable to heterogeneous resistance to vancomycin.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12654656      PMCID： PMC152514          DOI： 10.1128/AAC.47.4.1262-1266.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus.

Authors:  H F Chambers
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

2.  Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis.

Authors:  H F Chambers; S Kennedy
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

3.  Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users.

Authors:  P M Small; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

4.  Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis.

Authors:  R Dworkin; G Modin; S Kunz; R Rich; O Zak; M Sande
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

5.  Community-acquired methicillin-resistant Staphylococcus aureus infections in south Texas children.

Authors:  J E Fergie; K Purcell
Journal:  Pediatr Infect Dis J       Date:  2001-09       Impact factor: 2.129

6.  Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco.

Authors:  Edwin D Charlebois; David R Bangsberg; Nicholas J Moss; Matthew R Moore; Andrew R Moss; Henry F Chambers; Françoise Perdreau-Remington
Journal:  Clin Infect Dis       Date:  2002-01-02       Impact factor: 9.079

7.  Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  D P Levine; B S Fromm; B R Reddy
Journal:  Ann Intern Med       Date:  1991-11-01       Impact factor: 25.391

8.  Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus.

Authors:  H F Chambers; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

9.  Failure of vancomycin treatment in Staphylococcus aureus endocarditis. In vivo and in vitro observations.

Authors:  V Gopal; A L Bisno; F J Silverblatt
Journal:  JAMA       Date:  1976-10-04       Impact factor: 56.272

10.  Endocarditis due to methicillin-resistant Staphylococcus aureus in rabbits: expression of resistance to beta-lactam antibiotics in vivo and in vitro.

Authors:  H F Chambers; C J Hackbarth; T A Drake; M G Rusnak; M A Sande
Journal:  J Infect Dis       Date:  1984-06       Impact factor: 5.226
View more
  56 in total

Review 1.  Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.

Authors:  Catherine Liu; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

2.  Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Benjamin P Howden; Paul D R Johnson; Peter B Ward; Timothy P Stinear; John K Davies
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Successful treatment of right-sided prosthetic valve endocarditis due to methicillin-resistant teicoplanin-heteroresistant Staphylococcus aureus with linezolid.

Authors:  M Souli; K Pontikis; Z Chryssouli; I Galani; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-11       Impact factor: 3.267

Review 4.  Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective.

Authors:  B P Howden; P B Ward; P D R Johnson; P G P Charles; M L Grayson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

5.  Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method.

Authors:  Sarah W Satola; Monica M Farley; Karen F Anderson; Jean B Patel
Journal:  J Clin Microbiol       Date:  2010-11-03       Impact factor: 5.948

6.  Exposure of Staphylococcus aureus to subinhibitory concentrations of β-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus.

Authors:  Mélanie Roch; Perrine Clair; Adriana Renzoni; Marie-Elisabeth Reverdy; Olivier Dauwalder; Michèle Bes; Annie Martra; Anne-Marie Freydière; Frédéric Laurent; Philippe Reix; Oana Dumitrescu; François Vandenesch
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

7.  Rapid induction of high-level carbapenem resistance in heteroresistant KPC-producing Klebsiella pneumoniae.

Authors:  Sheila Adams-Sapper; Shantell Nolen; Grace Fox Donzelli; Mallika Lal; Kunihiko Chen; Livia Helena Justo da Silva; Beatriz M Moreira; Lee W Riley
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

8.  Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods.

Authors:  Michael J Rybak; Celine Vidaillac; Helio S Sader; Paul R Rhomberg; Hossein Salimnia; Lawrence E Briski; Audrey Wanger; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2013-04-17       Impact factor: 5.948

9.  Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.

Authors:  Tiffanny Jones; Michael R Yeaman; George Sakoulas; Soo-Jin Yang; Richard A Proctor; Hans-Georg Sahl; Jacques Schrenzel; Yan Q Xiong; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

10.  Synergy of arbekacin-based combinations against vancomycin hetero-intermediate Staphylococcus aureus.

Authors:  Ji Young Lee; Won Sup Oh; Kwan Soo Ko; Sang Taek Heo; Chi Sook Moon; Hyun Kyun Ki; Sungmin Kiem; Kyong Ran Peck; Jae Hoon Song
Journal:  J Korean Med Sci       Date:  2006-04       Impact factor: 2.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.